Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:CSTL NASDAQ:FLGT NASDAQ:TALK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$22.55-5.3%$15.27$5.26▼$24.34$246.57M0.5977,831 shs116,805 shsCSTLCastle Biosciences$23.85-1.9%$21.57$14.59▼$44.28$737.62M1.04363,644 shs336,700 shsFLGTFulgent Genetics$20.520.0%$17.32$13.46▼$31.04$583.07M0.94359,045 shs251,705 shsTALKTalkspace$5.20$5.20$2.22▼$5.23$871.07M1.052.38 million shs2.19 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix-5.29%+17.69%+38.17%+52.78%+299.54%CSTLCastle Biosciences-1.93%+10.52%+13.14%-4.79%+16.80%FLGTFulgent Genetics-0.05%+12.87%+13.12%+24.82%+3.22%TALKTalkspace0.00%0.00%0.00%+0.78%+87.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$22.55-5.3%$15.27$5.26▼$24.34$246.57M0.5977,831 shs116,805 shsCSTLCastle Biosciences$23.85-1.9%$21.57$14.59▼$44.28$737.62M1.04363,644 shs336,700 shsFLGTFulgent Genetics$20.520.0%$17.32$13.46▼$31.04$583.07M0.94359,045 shs251,705 shsTALKTalkspace$5.20$5.20$2.22▼$5.23$871.07M1.052.38 million shs2.19 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix-5.29%+17.69%+38.17%+52.78%+299.54%CSTLCastle Biosciences-1.93%+10.52%+13.14%-4.79%+16.80%FLGTFulgent Genetics-0.05%+12.87%+13.12%+24.82%+3.22%TALKTalkspace0.00%0.00%0.00%+0.78%+87.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.80Moderate Buy$28.3325.65% UpsideCSTLCastle Biosciences 2.80Moderate Buy$42.4377.90% UpsideFLGTFulgent Genetics 2.20Hold$27.0031.58% UpsideTALKTalkspace 2.00Hold$5.566.97% UpsideCurrent Analyst Ratings BreakdownLatest BDSX, TALK, CSTL, and FLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026BDSXBiodesix Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.006/24/2026CSTLCastle Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/24/2026BDSXBiodesix Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026CSTLCastle Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/18/2026BDSXBiodesix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $27.006/15/2026BDSXBiodesix HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.006/15/2026BDSXBiodesix HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2026BDSXBiodesix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026CSTLCastle Biosciences KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.005/26/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$88.50M2.64N/AN/A($0.31) per share-72.74CSTLCastle Biosciences$344.23M2.10$1.09 per share21.85$16.13 per share1.48FLGTFulgent Genetics$322.67M1.81N/AN/A$35.80 per share0.57TALKTalkspace$228.87M3.81$0.06 per share80.75$0.71 per share7.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%8/6/2026 (Estimated)CSTLCastle Biosciences-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%8/3/2026 (Estimated)FLGTFulgent Genetics-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%7/31/2026 (Estimated)TALKTalkspace$7.79M$0.01520.5223.64N/A0.49%1.03%0.88%8/4/2026 (Estimated)Latest BDSX, TALK, CSTL, and FLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026TALKTalkspace$0.02-$0.04-$0.06-$0.04$63.32 million$61.68 million5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million5/4/2026Q1 2026BDSXBiodesix-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ATALKTalkspaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix5.092.822.82CSTLCastle Biosciences0.026.756.53FLGTFulgent GeneticsN/A5.315.31TALKTalkspaceN/A4.844.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%CSTLCastle Biosciences92.60%FLGTFulgent Genetics48.06%TALKTalkspace57.37%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix23.20%CSTLCastle Biosciences6.10%FLGTFulgent Genetics36.18%TALKTalkspace23.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix22010.36 million7.95 millionNo DataCSTLCastle Biosciences54030.33 million28.48 millionOptionableFLGTFulgent Genetics1,31528.40 million18.13 millionOptionableTALKTalkspace500167.51 million128.15 millionOptionableBDSX, TALK, CSTL, and FLGT HeadlinesRecent News About These CompaniesComparing Talkspace (NASDAQ:TALK) and Zhongchao (NASDAQ:ZCMD)June 30 at 3:52 AM | americanbankingnews.comApple’s Price Hike Backfires on Wall StreetJune 26, 2026 | cheddar.comCMeet the AI designed for mental health, not just conversationJune 25, 2026 | msn.comAI and mental health: Tool, trend, or the future of therapy?June 23, 2026 | msn.comTalkspace (NASDAQ:TALK) Insider John Charles Reilly Sells 40,289 SharesJune 23, 2026 | americanbankingnews.comTalkspace, Inc. (NASDAQ:TALK) Given Consensus Recommendation of "Hold" by AnalystsJune 23, 2026 | americanbankingnews.comInsider Selling: Talkspace (NASDAQ:TALK) Insider Sells $209,502.80 in StockJune 23, 2026 | insidertrades.comJohn Charles Reilly Sells 55,144 Shares of Talkspace (NASDAQ:TALK) StockJune 17, 2026 | insidertrades.comTalkspace Just Launched an AI Therapist—With 1 Major CatchJune 13, 2026 | inc.comWill AI replace therapists? What experts sayJune 10, 2026 | aol.comATalkspace Announces ‘Tee,’ the First Safe AI Agent Specifically Developed to Help Individuals Navigate Life’s Daily Mental Health ChallengesJune 9, 2026 | finance.yahoo.comTalkspace Announces ‘Tee,' the First Safe AI Agent Specifically Developed to Help Individuals Navigate Life's Daily Mental Health ChallengesJune 9, 2026 | businesswire.comTalkspace Stockholders Vote to Approve Acquisition by UHSMay 29, 2026 | globenewswire.comWhy billionaire George Soros is betting big on Talkspace stockMay 24, 2026 | msn.comTALKW Talkspace, Inc. WT EXP 062126May 21, 2026 | seekingalpha.comCourt case exposes privacy risks in digital therapy appsMay 13, 2026 | msn.comCourt records are raising questions about the privacy of digital therapy platformsMay 13, 2026 | msn.comThe Fitbit app becomes Google Health, Canvas suffers major data breach, Talkspace expands U.S. Navy partnershipMay 8, 2026 | vator.tvVTalkspace expands U.S. Navy mental health partnership to 13 basesMay 7, 2026 | mobihealthnews.comMTalkspace Equity Warrant Exp 22 June 2026May 6, 2026 | cnbc.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDSX, TALK, CSTL, and FLGT Company DescriptionsBiodesix NASDAQ:BDSX$22.55 -1.26 (-5.29%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$22.62 +0.07 (+0.32%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Castle Biosciences NASDAQ:CSTL$23.85 -0.47 (-1.93%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$23.38 -0.47 (-1.97%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Fulgent Genetics NASDAQ:FLGT$20.52 -0.01 (-0.05%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$20.52 +0.00 (+0.02%) As of 06/30/2026 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Talkspace NASDAQ:TALK$5.20 0.00 (0.00%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$5.22 +0.02 (+0.37%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Talkspace, Inc. operates as a virtual behavioral healthcare company in the United States. The company offers psychotherapy and psychiatry services through its platform to individuals, enterprises, and health plans and employee assistance programs. It provides text, audio, and video-based psychotherapy from licensed therapists. The company offers Talkspace Employee Assistance Program (EAP) and Talkspace Behavioral Health plan (BH) that provides online therapy to members through BH and EAP offerings; and Talkspace for Business for members to access its platform services on a benefit plan paid by the enterprise. It serves its platform through third-party platforms or marketplace, such as Apple App Store and Google Play App Store. Talkspace, Inc. was founded in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
